Wolfram Brugger
Overview
Explore the profile of Wolfram Brugger including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
52
Citations
2809
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Roddie C, Sandhu K, Tholouli E, Logan A, Shaughnessy P, Barba P, et al.
N Engl J Med
. 2024 Nov;
391(23):2219-2230.
PMID: 39602653
Background: Obecabtagene autoleucel (obe-cel) is an autologous 41BB-ζ anti-CD19 chimeric antigen receptor (CAR) T-cell therapy which uses an intermediate-affinity CAR to reduce toxic effects and improve persistence. Methods: We conducted...
2.
Cwynarski K, Iacoboni G, Tholouli E, Menne T, Irvine D, Balasubramaniam N, et al.
Nat Med
. 2024 Nov;
31(1):137-143.
PMID: 39528665
Relapsed/refractory peripheral T cell lymphomas (PTCLs) are aggressive tumors with a poor prognosis. Unlike B cell lymphomas, treatment of PTCL has not benefited from advances in immunotherapy. This is largely...
3.
Bresser H, Schmoor C, Grishina O, Pfeifer D, Thomas J, Rehman U, et al.
Eur J Haematol
. 2024 Oct;
114(2):231-237.
PMID: 39400388
In a randomized phase II trial (AMLSG 14-09, NCT00867672) of elderly, newly diagnosed AML patients, ATRA combined with decitabine (DEC) significantly improved the overall response rate (ORR) and survival also...
4.
Roddie C, Lekakis L, Marzolini M, Ramakrishnan A, Zhang Y, Hu Y, et al.
Blood
. 2023 Feb;
141(20):2470-2482.
PMID: 36821767
Relapse after CD19-directed chimeric antigen receptor T-cell (CAR-T) therapy for large B-cell lymphoma (LBCL) is commonly ascribed to antigen loss or CAR-T exhaustion. Multiantigen targeting and programmed cell death protein-1...
5.
Rummelt C, Grishina O, Schmoor C, Crysandt M, Heuser M, Gotze K, et al.
Haematologica
. 2023 Jan;
108(8):2244-2248.
PMID: 36601981
No abstract available.
6.
Staber P, Jurczak W, Greil R, Vucinic V, Middeke J, Montillo M, et al.
Leuk Lymphoma
. 2021 Aug;
62(14):3440-3451.
PMID: 34414843
Patients with relapsed/refractory chronic lymphocytic leukemia (R/R CLL) whose treatment failed with a Bruton's tyrosine kinase inhibitor have poor outcomes. We investigated tafasitamab plus idelalisib (cohort A) or venetoclax (cohort...
7.
Klisovic R, Leung W, Brugger W, Dirnberger-Hertweck M, Winderlich M, Ambarkhane S, et al.
Cancer
. 2021 Aug;
127(22):4190-4197.
PMID: 34343354
Background: B-precursor cell acute lymphoblastic leukemia (B-ALL) in adults is an aggressive and challenging condition, and patients with relapsed/refractory (R/R) disease after allogeneic stem cell transplantation (SCT), or noncandidates for...
8.
Straka C, Salwender H, Knop S, Vogel M, Muller J, Metzner B, et al.
Eur J Haematol
. 2021 Jul;
107(5):529-542.
PMID: 34270825
Objective: A post hoc subgroup analysis of two phase III trials (NCT00416273, NCT00416208) was carried out to investigate the influence of 100/140 and 200 mg/m² melphalan as well as single/double...
9.
Lubbert M, Grishina O, Schmoor C, Schlenk R, Jost E, Crysandt M, et al.
J Clin Oncol
. 2019 Dec;
38(3):257-270.
PMID: 31794324
Purpose: DNA-hypomethylating agents are studied in combination with other epigenetic drugs, such as histone deacetylase inhibitors or differentiation inducers (eg, retinoids), in myeloid neoplasias. A randomized, phase II trial with...
10.
Straka C, Knop S, Vogel M, Muller J, Kropff M, Metzner B, et al.
Eur J Haematol
. 2019 Jun;
103(3):255-267.
PMID: 31231828
Objective: A post hoc analysis of two phase III trials was carried out to explore the influence of age and treatment factors on the effect of bortezomib consolidation on progression-free...